{
  "synthesized_claims": [
    {
      "statement": "OMM cholesterol depletion (e.g., 50% \u2193[Chol]/[CL]) will sensitize cancer cells to VDAC-engaging therapies (e.g., erastin, CBD) but with a predicted therapeutic index fold-change of only ~2-3x, not 5-8x, due to concomitant toxicity in normal cells from membrane disruption.",
      "mechanism": "While [Chol]/[CL] reduction multiplicatively lowers T, cholesterol is essential for normal membrane integrity; its depletion non-selectively increases baseline mitochondrial permeability, narrowing the window for selective cancer cell killing.",
      "falsifiable_by": "In vivo xenograft data showing M\u03b2CD + erastin yields a >5x improvement in the TD50/ED50 ratio without significant host toxicity.",
      "type": 1,
      "confidence": 0.733,
      "overlap_count": 3,
      "models": [
        "claude",
        "deepseek",
        "gemini"
      ],
      "tuples": "frozenset({('cancer_cell', 'downregulates', 'cl'), ('cancer_cell', 'upregulates', 'cl')})",
      "chunk_text": "OMM cholesterol depletion (e.g., 50% \u2193[Chol]/[CL]) will sensitize cancer cells to VDAC-engaging therapies (e.g., erastin, CBD) but with a predicted therapeutic index fold-change of only ~2-3x, not 5-8x, due to concomitant toxicity in normal cells from membrane disruption."
    },
    {
      "statement": "The optimal two-drug pair is context-dependent, not universally 2-DG + ABT-737. When one f-term is near saturation (>0.9), combining its displacement with cholesterol reduction yields greater fold-change than targeting both f-terms when both are moderate (~0.7). Numerically: if f_HKII=0.95, reducing it to 0.5 changes (1-f) from 0.05\u21920.5 (10\u00d7 gain), dwarfing a 3\u00d7 gain from also targeting f_BclxL at 0.7\u21920.3. Adding statin to the saturated-term drug gives ~15-20\u00d7 Threshold reduction.",
      "mechanism": "Reciprocal denominator structure creates asymmetric sensitivity \u2014 the term nearest 1.0 contributes disproportionately, so targeting it plus [Chol]/[CL] maximizes multiplicative gain.",
      "falsifiable_by": "Isobologram studies showing 2-DG+ABT-737 consistently outperforms statin+ABT-737 even in tumors with f_BclxL>0.9.",
      "type": 2,
      "confidence": 0.675,
      "overlap_count": 2,
      "models": [
        "claude",
        "mistral"
      ],
      "tuples": "frozenset({('abt', 'downregulates', 'cl')})",
      "chunk_text": "The optimal two-drug pair is context-dependent, not universally 2-DG + ABT-737. When one f-term is near saturation (>0.9), combining its displacement with cholesterol reduction yields greater fold-change than targeting both f-terms when both are moderate (~0.7). Numerically: if f_HKII=0.95, reducing it to 0.5 changes (1-f) from 0.05\u21920.5 (10\u00d7 gain), dwarfing a 3\u00d7 gain from also targeting f_BclxL at 0.7\u21920.3. Adding statin to the saturated-term drug gives ~15-20\u00d7 Threshold reduction."
    },
    {
      "statement": "A biomarker panel (f_HKII by subcellular fractionation, f_BclxL by BIM/BAX sequestration assay, [Chol]/[CL] by lipidomics, GSH/GSSG) can stratify patients into mechanistically guided combination therapy groups with >80% predicted accuracy.",
      "mechanism": "The quantitative value of each variable directly inputs into the cofactor equation, allowing calculation of the required correction magnitude and identification of the most efficient drug targets for each patient.",
      "falsifiable_by": "A prospective clinical trial where biomarker-guided assignment fails to improve response rates over standard care. \u2500\u2500\u2500 **",
      "type": 2,
      "confidence": 0.625,
      "overlap_count": 2,
      "models": [
        "claude",
        "deepseek"
      ],
      "tuples": "frozenset({('bim', 'interacts', 'bax'), ('cl', 'interacts', 'gsh'), ('bax', 'interacts', 'cl'), ('gsh', 'interacts', 'gssg')})",
      "chunk_text": "A biomarker panel (f_HKII by subcellular fractionation, f_BclxL by BIM/BAX sequestration assay, [Chol]/[CL] by lipidomics, GSH/GSSG) can stratify patients into mechanistically guided combination therapy groups with >80% predicted accuracy."
    },
    {
      "statement": "The \"weakest link\" is identifiable by pre-treatment proteolipidomics: f_HKII dominates in glycolytic tumors (e.g., GBM, HCC), f_BclxL in hematologic malignancies (e.g., AML, CLL), and [Chol]/[CL] in lipid-raft addicted cancers (e.g., prostate, some lymphomas).",
      "mechanism": "Lineage-specific oncogenic programs drive the differential overexpression and OMM localization of HK-II, Bcl-xL, or cholesterol synthesis enzymes, making one term the primary governor of Threshold.",
      "falsifiable_by": "CRISPR knockout of the predicted dominant factor (e.g., HK-II in AML) failing to lower T or sensitize to apoptosis, while knockout of the minor factor does.",
      "type": 3,
      "confidence": 0.9,
      "overlap_count": 1,
      "models": [
        "deepseek"
      ],
      "tuples": "frozenset({('gbm', 'interacts', 'hcc'), ('cl', 'interacts', 'omm'), ('aml', 'interacts', 'cll'), ('hcc', 'interacts', 'aml'), ('omm', 'interacts', 'hk'), ('cll', 'interacts', 'cl')})",
      "chunk_text": "The \"weakest link\" is identifiable by pre-treatment proteolipidomics: f_HKII dominates in glycolytic tumors (e.g., GBM, HCC), f_BclxL in hematologic malignancies (e.g., AML, CLL), and [Chol]/[CL] in lipid-raft addicted cancers (e.g., prostate, some lymphomas)."
    },
    {
      "statement": "In GBM (f_HKII~0.9, f_BclxL~0.6), HK-II displacement is rate-limiting; in AML (f_BclxL~0.9, f_HKII~0.5), Bcl-xL is rate-limiting. The weakest link is the highest-f term. Venetoclax succeeds in AML precisely because it addresses the dominant term.",
      "mechanism": "Venetoclax's clinical efficacy in AML but not solid tumors maps onto f_BclxL dominance in hematologic malignancies.",
      "falsifiable_by": "Single-cell OMM proteomics showing f_HKII>f_BclxL in AML blasts.",
      "type": 3,
      "confidence": 0.88,
      "overlap_count": 1,
      "models": [
        "claude"
      ],
      "tuples": "frozenset({('gbm', 'interacts', 'hk'), ('hk', 'interacts', 'aml')})",
      "chunk_text": "In GBM (f_HKII~0.9, f_BclxL~0.6), HK-II displacement is rate-limiting; in AML (f_BclxL~0.9, f_HKII~0.5), Bcl-xL is rate-limiting. The weakest link is the highest-f term. Venetoclax succeeds in AML precisely because it addresses the dominant term."
    },
    {
      "statement": "The optimal two-drug synergy is achieved by combining an OMM cholesterol-depleting agent (statin) with a drug displacing the most saturated VDAC-binding protein (the one with `f` closest to 1.0), exceeding the synergy of any two protein-displacing agents.",
      "mechanism": "This combination exploits two orthogonal, multiplicative terms; targeting the most saturated protein yields the largest fold-change in the `(1-f)` term, which is then multiplied by the lipid term reduction.",
      "falsifiable_by": "Isobologram analysis of a high `f_HKII` cancer cell line (e.g., U87) showing that the combination of 2-DG + ABT-737 has a significantly higher combination index than 2-DG + a statin.",
      "type": 3,
      "confidence": 0.85,
      "overlap_count": 1,
      "models": [
        "gemini"
      ],
      "tuples": "frozenset({('omm', 'interacts', 'vdac')})",
      "chunk_text": "The optimal two-drug synergy is achieved by combining an OMM cholesterol-depleting agent (statin) with a drug displacing the most saturated VDAC-binding protein (the one with `f` closest to 1.0), exceeding the synergy of any two protein-displacing agents."
    },
    {
      "statement": "The optimal two-drug synergy for maximal Threshold reduction is context-dependent: for most solid tumors with high glycolytic flux, 2-DG (\u2193f_HKII) + a Bcl-2/xL inhibitor (\u2193f_BclxL) is superior; for tumors with high OMM cholesterol, a statin/M\u03b2CD (\u2193[Chol]/[CL]) + the dominant occupancy-reducing drug is optimal.",
      "mechanism": "The multiplicative equation dictates that the largest fold-reduction in T comes from simultaneously targeting the term with the highest baseline value and the term whose manipulation induces the largest relative change.",
      "falsifiable_by": "A systematic in vitro screen across cell lines showing a different combination (e.g., statin+2-DG) consistently outperforms Bcl-xL inhibitor+2-DG in glycolytic models.",
      "type": 3,
      "confidence": 0.85,
      "overlap_count": 1,
      "models": [
        "deepseek"
      ],
      "tuples": "frozenset({('omm', 'interacts', 'cl'), ('dg', 'interacts', 'omm')})",
      "chunk_text": "The optimal two-drug synergy for maximal Threshold reduction is context-dependent: for most solid tumors with high glycolytic flux, 2-DG (\u2193f_HKII) + a Bcl-2/xL inhibitor (\u2193f_BclxL) is superior; for tumors with high OMM cholesterol, a statin/M\u03b2CD (\u2193[Chol]/[CL]) + the dominant occupancy-reducing drug is optimal."
    },
    {
      "statement": "In highly glycolytic tumors (e.g., GBM), metabolic stress induced by metformin will synergize most strongly with direct HK-II inhibitors (e.g., 3-BrPA), not Bcl-xL inhibitors.",
      "mechanism": "These tumors are addicted to the high `f_HKII` term; metformin creates an energy crisis that prevents compensatory responses, while a direct HK-II inhibitor strikes the primary survival dependency, causing catastrophic gate failure.",
      "falsifiable_by": "A synthetic lethality screen showing that metformin plus a Bcl-xL inhibitor (ABT-737) induces more apoptosis in patient-derived GBM spheroids than metformin plus an HK-II inhibitor. \u2500\u2500\u2500",
      "type": 3,
      "confidence": 0.8,
      "overlap_count": 1,
      "models": [
        "gemini"
      ],
      "tuples": "frozenset({('gbm', 'upregulates', 'hk')})",
      "chunk_text": "In highly glycolytic tumors (e.g., GBM), metabolic stress induced by metformin will synergize most strongly with direct HK-II inhibitors (e.g., 3-BrPA), not Bcl-xL inhibitors."
    },
    {
      "statement": "2**: OMM cholesterol depletion (M\u03b2CD, 50% \u2193[Chol]/[CL]) sensitizes cancer cells to erastin/CBD with a **3\u20135\u00d7 TI fold-change in vitro**, but **<2\u00d7 in vivo** due to systemic toxicity (e.g., membrane destabilization in normal cells). **TYPE**: 1 (quantitative prediction) **CONFIDENCE**: 0.75 **MECHANISM**: [Chol]/[CL] reduction directly multiplies *Threshold*; erastin/CBD\u2019s efficacy scales inversely. However, M\u03b2CD\u2019s narrow therapeutic window (TI < 10) limits clinical utility. Statins (e.g., simvastatin) may achieve 2\u20133\u00d7 TI with better safety. **FALSIFIABLE BY**: In vivo TI measurements <2\u00d7 or lack of supra-additivity in cholesterol-depleted xenografts. ---",
      "mechanism": ": [Chol]/[CL] reduction directly multiplies *Threshold*; erastin/CBD\u2019s efficacy scales inversely. However, M\u03b2CD\u2019s narrow therapeutic window (TI < 10) limits clinical utility. Statins (e.g., simvastatin) may achieve 2\u20133\u00d7 TI with better safety.",
      "falsifiable_by": ": In vivo TI measurements <2\u00d7 or lack of supra-additivity in cholesterol-depleted xenografts. ---",
      "type": 3,
      "confidence": 0.5,
      "overlap_count": 1,
      "models": [
        "mistral"
      ],
      "tuples": "frozenset({('omm', 'interacts', 'cl'), ('type', 'interacts', 'confidence'), ('mechanism', 'interacts', 'falsifiable'), ('cbd', 'interacts', 'ti'), ('cl', 'interacts', 'cancer_cell'), ('falsifiable', 'interacts', 'by'), ('confidence', 'interacts', 'mechanism'), ('ti', 'interacts', 'healthy_cell'), ('cancer_cell', 'interacts', 'cbd'), ('healthy_cell', 'interacts', 'type')})",
      "chunk_text": "2**: OMM cholesterol depletion (M\u03b2CD, 50% \u2193[Chol]/[CL]) sensitizes cancer cells to erastin/CBD with a **3\u20135\u00d7 TI fold-change in vitro**, but **<2\u00d7 in vivo** due to systemic toxicity (e.g., membrane destabilization in normal cells). **TYPE**: 1 (quantitative prediction) **CONFIDENCE**: 0.75 **MECHANISM**: [Chol]/[CL] reduction directly multiplies *Threshold*; erastin/CBD\u2019s efficacy scales inversely. However, M\u03b2CD\u2019s narrow therapeutic window (TI < 10) limits clinical utility. Statins (e.g., simvast"
    },
    {
      "statement": "3**: Metabolic crisis (2-DG + metformin) + venetoclax will **collapse the apoptotic gate in AML/multiple myeloma** but **fail in GBM** due to differential term dominance (*f_BclxL* > *f_HKII* in hematologic cancers vs. *f_HKII* > *f_BclxL* in GBM). **TYPE**: 0 (empirically supported) **CONFIDENCE**: 0.90 **MECHANISM**: AML relies on Bcl-xL (venetoclax-sensitive), while GBM is HK-II-addicted (metformin/2-DG insufficient to overcome *f_HKII* > 0.8). CRISPR screens confirm this dependency split. **FALSIFIABLE BY**: Single-cell proteomics showing *f_BclxL* > *f_HKII* in GBM or *f_HKII* > *f_BclxL* in AML. ---",
      "mechanism": ": AML relies on Bcl-xL (venetoclax-sensitive), while GBM is HK-II-addicted (metformin/2-DG insufficient to overcome *f_HKII* > 0.8). CRISPR screens confirm this dependency split.",
      "falsifiable_by": ": Single-cell proteomics showing *f_BclxL* > *f_HKII* in GBM or *f_HKII* > *f_BclxL* in AML. ---",
      "type": 3,
      "confidence": 0.5,
      "overlap_count": 1,
      "models": [
        "mistral"
      ],
      "tuples": "frozenset({('type', 'interacts', 'confidence'), ('aml', 'interacts', 'gbm'), ('gbm', 'interacts', 'type'), ('falsifiable', 'interacts', 'by'), ('confidence', 'interacts', 'mechanism'), ('hk', 'interacts', 'crispr'), ('crispr', 'interacts', 'falsifiable'), ('dg', 'interacts', 'aml'), ('mechanism', 'interacts', 'hk')})",
      "chunk_text": "3**: Metabolic crisis (2-DG + metformin) + venetoclax will **collapse the apoptotic gate in AML/multiple myeloma** but **fail in GBM** due to differential term dominance (*f_BclxL* > *f_HKII* in hematologic cancers vs. *f_HKII* > *f_BclxL* in GBM). **TYPE**: 0 (empirically supported) **CONFIDENCE**: 0.90 **MECHANISM**: AML relies on Bcl-xL (venetoclax-sensitive), while GBM is HK-II-addicted (metformin/2-DG insufficient to overcome *f_HKII* > 0.8). CRISPR screens confirm this dependency split. **"
    },
    {
      "statement": "4**: The biomarker panel (GSH/GSSG ratio, f_HKII occupancy, [Chol]/[CL]) can **predict response to gate-restoring combinations with >80% accuracy** in hematologic cancers but **<60% in solid tumors** due to heterogeneity. **TYPE**: 1 (hypothesis) **CONFIDENCE**: 0.70 **MECHANISM**: GSH/GSSG reflects redox status (linked to [Chol]/[CL]), while f_HKII/f_BclxL occupancy correlates with term dominance.",
      "mechanism": ": GSH/GSSG reflects redox status (linked to [Chol]/[CL]), while f_HKII/f_BclxL occupancy correlates with term dominance.",
      "falsifiable_by": "",
      "type": 3,
      "confidence": 0.5,
      "overlap_count": 1,
      "models": [
        "mistral"
      ],
      "tuples": "frozenset({('type', 'interacts', 'confidence'), ('cl', 'interacts', 'type'), ('gsh', 'interacts', 'gssg'), ('confidence', 'interacts', 'mechanism'), ('gssg', 'interacts', 'cl')})",
      "chunk_text": "4**: The biomarker panel (GSH/GSSG ratio, f_HKII occupancy, [Chol]/[CL]) can **predict response to gate-restoring combinations with >80% accuracy** in hematologic cancers but **<60% in solid tumors** due to heterogeneity. **TYPE**: 1 (hypothesis) **CONFIDENCE**: 0.70 **MECHANISM**: GSH/GSSG reflects redox status (linked to [Chol]/[CL]), while f_HKII/f_BclxL occupancy correlates with term dominance."
    },
    {
      "statement": "2-DG (\u2193f_HKII 50% at 5mM) + ABT-737 (\u2193f_BclxL 70%",
      "mechanism": "",
      "falsifiable_by": "",
      "type": 3,
      "confidence": 0.5,
      "overlap_count": 1,
      "models": [
        "grok"
      ],
      "tuples": "frozenset({('dg', 'interacts', 'abt')})",
      "chunk_text": "2-DG (\u2193f_HKII 50% at 5mM) + ABT-737 (\u2193f_BclxL 70%"
    }
  ],
  "conflicts": [],
  "total_rounds": 0,
  "snapshots": [
    {
      "round_num": 0,
      "jaccard": 0.010597826086956521,
      "cosine": 0.5488138854503631,
      "jsd": 0.3897872026970988,
      "kappa": 0.6651376146788992,
      "type_distribution": {
        "0": 0.0,
        "1": 0.5625,
        "2": 0.375,
        "3": 0.0625
      },
      "type_01_ratio": 0.5625,
      "n_claims_per_model": [
        4,
        4,
        1,
        3,
        4
      ]
    },
    {
      "round_num": 1,
      "jaccard": 0.07963334323628442,
      "cosine": 0.581014358997345,
      "jsd": 0.16634543295593868,
      "kappa": 0.9058577405857741,
      "type_distribution": {
        "0": 0.0,
        "1": 0.1875,
        "2": 0.25,
        "3": 0.5625
      },
      "type_01_ratio": 0.1875,
      "n_claims_per_model": [
        4,
        4,
        1,
        3,
        4
      ]
    }
  ]
}